Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination

Overview of attention for article published in Frontiers in Drug Safety and Regulation, August 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (55th percentile)
Above-average Attention Score compared to outputs of the same age and source (57th percentile)

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 8,715 followers.

RT @FrontPharmacol: New Research: Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination https://t.co/di2haX…

New Research: Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination https://t.co/di2haXxjej #FrontiersIn #DrugSafetyRegulation

RT @FrontDrugDDS: New Research: Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination #DrugSafetyandRegulat…

New Research: Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination #DrugSafetyandRegulation https://t.co/x1ZZ2uaCYR

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.